Inventor · disambiguated record
David V. Erbe
Also filed as: ERBE DAVID · ERBE DAVID R · ERBE DAVID V
11 granted patents·20 pending applications·97 citations·filing 1994–2024
88Inventor score
Files withALNYLAM PHARMACEUTICALS INC17WYETH CORP4AXCELLA HEALTH INC3ELEVEN BIOTHERAPEUTICS INC2PRONUTRIA INC2
Top patents by PatentIndex Score
31 records- 0191US9878004B2Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereofPRONUTRIA INC·Filed 2014·Granted Jan 30, 2018·24 cites·14 claims
- 0289US7521473B2Inhibitors of protein tyrosine phosphatase 1BWYETH CORP·Filed 2005·Granted Apr 21, 2009·23 cites·59 claims
- 0385US10478500B2Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Nov 19, 2019·4 cites·19 claims
- 0483US10844384B2Glucokinase (GCK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 24, 2020·1 cites·38 claims
- 0583US2025017953A1LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0683US2025064936A1Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0782US9951130B2IL-6 antagonists and uses thereofELEVEN BIOTHERAPEUTICS INC·Filed 2014·Granted Apr 24, 2018·7 cites·20 claims
- 0879US5593882ASelectin variantsGENENTECH INC·Filed 1994·Granted Jan 14, 1997·38 cites·25 claims
- 0979US2024287524A1GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1077US2023121944A1Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1175US11446380B2Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Sep 20, 2022·0 cites·16 claims
- 1272US11859185B2Glucokinase (GCK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jan 2, 2024·0 cites·26 claims
- 1369US2024209372A1Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1469US2020113927A1LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1567US2024309375A1Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disordersALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1666US2021228614A1LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1766US2022347262A1Compositions and Formulations and Methods of Production and Use ThereofAXCELLA HEALTH INC·Filed 2021·Application pending·0 cites
- 1865US2020206258A1LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1961US2009048286A1Inhibitors of Protein Tyrosine Phosphatase 1BWYETH CORP·Filed 2008·Application pending·0 cites
- 2061US2024344070A1Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorderALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2159US2022403394A1Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2257US11459386B2IL-6 antagonists and uses thereofELEVEN BIOTHERAPEUTICS INC·Filed 2018·Granted Oct 4, 2022·0 cites·10 claims
- 2357US2020405807A1Compositions and Formulations and Methods of Production and Use ThereofAXCELLA HEALTH INC·Filed 2020·Application pending·0 cites
- 2457US2018125926A1Compositions and Formulations and Methods of Production and Use ThereofAXCELLA HEALTH INC·Filed 2017·Application pending·0 cites
- 2556US2023183706A1Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variantALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2655US11261447B2Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 1, 2022·0 cites·18 claims
- 2754US2016228506A1Compositions and Formulations for Prevention and Reduction of Tumorigenesis, Cancer Cell Proliferation and Invasion, and Methods of Production and Use Thereof in Cancer TreatmentPRONUTRIA INC·Filed 2014·Application pending·0 cites
- 2851US2005203081A1Inhibitors of protein tyrosine phosphatase 1BFiled 2005·Application pending·0 cites
- 2949US2008004325A1PTP1B inhibitorsWYETH CORP·Filed 2007·Application pending·0 cites
- 3044US2007197770A1Method Of Production And Apparatus For Producing Of Rubbery PolymerHIKIDA KAZUHIRO·Filed 2005·Application pending·0 cites
- 3141US7674822B2PTP1b inhibitorsWYETH CORP·Filed 2005·Granted Mar 9, 2010·0 cites·65 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →